161 related articles for article (PubMed ID: 28188752)
1. Comparison of 5 Ki-67 antibodies regarding reproducibility and capacity to predict prognosis in breast cancer: does the antibody matter?
Ács B; Kulka J; Kovács KA; Teleki I; Tőkés AM; Meczker Á; Győrffy B; Madaras L; Krenács T; Szász AM
Hum Pathol; 2017 Jul; 65():31-40. PubMed ID: 28188752
[TBL] [Abstract][Full Text] [Related]
2. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer.
Rudolph P; Alm P; Heidebrecht HJ; Bolte H; Ratjen V; Baldetorp B; Fernö M; Olsson H; Parwaresch R
J Natl Cancer Inst; 1999 Feb; 91(3):271-8. PubMed ID: 10037106
[TBL] [Abstract][Full Text] [Related]
3. Reproducibility and Prognostic Potential of Ki-67 Proliferation Index when Comparing Digital-Image Analysis with Standard Semi-Quantitative Evaluation in Breast Cancer.
Ács B; Madaras L; Kovács KA; Micsik T; Tőkés AM; Győrffy B; Kulka J; Szász AM
Pathol Oncol Res; 2018 Jan; 24(1):115-127. PubMed ID: 28401450
[TBL] [Abstract][Full Text] [Related]
4. Ki 67 assessment in breast cancer in an Egyptian population: a comparative study between manual assessment on optical microscopy and digital quantitative assessment.
Ayad E; Soliman A; Anis SE; Salem AB; Hu P; Dong Y
Diagn Pathol; 2018 Aug; 13(1):63. PubMed ID: 30153851
[TBL] [Abstract][Full Text] [Related]
5. An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications.
Vörös A; Csörgő E; Nyári T; Cserni G
Pathobiology; 2013; 80(3):111-8. PubMed ID: 23258384
[TBL] [Abstract][Full Text] [Related]
6. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer.
Veronese SM; Maisano C; Scibilia J
Anticancer Res; 1995; 15(6B):2717-22. PubMed ID: 8669852
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical assessment of proliferation rate of breast carcinoma cells using Ki-67, MIB-1 and anti-PCNA monoclonal antibodies.
Markiewski M; Domagała W
Pol J Pathol; 1996; 47(4):189-94. PubMed ID: 9097711
[TBL] [Abstract][Full Text] [Related]
8. Importance of Ki-67 in human epidermal growth factor receptor 2 positive breast cancer.
Erdogan B; Turkmen E; Yalta TD; Usta U; Kodaz H; Hacibekiroglu İ; Tanriverdi O; Uzunoglu S; Cicin I
J BUON; 2015; 20(3):730-6. PubMed ID: 26214624
[TBL] [Abstract][Full Text] [Related]
9. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer.
Thor AD; Liu S; Moore DH; Edgerton SM
J Clin Oncol; 1999 Feb; 17(2):470-7. PubMed ID: 10080587
[TBL] [Abstract][Full Text] [Related]
10. Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.
Hida AI; Bando K; Sugita A; Maeda T; Ueda N; Matsukage S; Nakanishi M; Kito K; Miyazaki T; Ohtsuki Y; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Aogi K; Moriya T
J Clin Pathol; 2015 May; 68(5):356-61. PubMed ID: 25673730
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer.
Billgren AM; Tani E; Liedberg A; Skoog L; Rutqvist LE
Breast Cancer Res Treat; 2002 Jan; 71(2):161-70. PubMed ID: 11881912
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactivity to MIB-1 in breast cancer: methodological assessment and comparison with other proliferation indices.
Benini E; Rao S; Daidone MG; Pilotti S; Silvestrini R
Cell Prolif; 1997; 30(3-4):107-15. PubMed ID: 9375023
[TBL] [Abstract][Full Text] [Related]
13. BGX-Ki-67 index as a supplementary marker to MIB-1 index, enabling more precise distinction between luminal A and B subtypes of breast carcinoma and eliminating the problem of membranous/cytoplasmic MIB-1 staining.
Niemiec J; Adamczyk A; Ambicka A; Mucha-Małecka A; Wysocki WM; Majchrzyk K; Ryś J
Am J Clin Pathol; 2015 Mar; 143(3):419-29. PubMed ID: 25696801
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein.
Domagala W; Markiewski M; Harezga B; Dukowicz A; Osborn M
Clin Cancer Res; 1996 Jan; 2(1):147-54. PubMed ID: 9816101
[TBL] [Abstract][Full Text] [Related]
15. The prognostic relevance of estimates of proliferative activity in early breast cancer.
Offersen BV; Sørensen FB; Knoop A; Overgaard J;
Histopathology; 2003 Dec; 43(6):573-82. PubMed ID: 14636258
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct.
Suto T; Sugai T; Nakamura S; Funato O; Nitta H; Sasaki R; Kanno S; Saito K
Cancer; 1998 Jan; 82(1):86-95. PubMed ID: 9428483
[TBL] [Abstract][Full Text] [Related]
17. Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma.
MacGrogan G; Jollet I; Huet S; Sierankowski G; Picot V; Bonichon F; Coindre JM
Mod Pathol; 1997 Aug; 10(8):769-76. PubMed ID: 9267818
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer.
Neri A; Marrelli D; Pedrazzani C; Caruso S; De Stefano A; Mariani F; Megha T; De Marco G; Corso G; Pinto E; Roviello F
Eur J Surg Oncol; 2008 Dec; 34(12):1299-303. PubMed ID: 18164172
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer.
Cubukcu E; Kanat O; Fatih Olmez O; Kabul S; Canhoroz M; Avci N; Deligonul A; Hartavi M; Cubukcu S; Olmez F; Kurt E; Evrensel T; Gokgoz S; Manavoglu O
J BUON; 2013; 18(2):359-65. PubMed ID: 23818346
[TBL] [Abstract][Full Text] [Related]
20. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
